Mithra Pharmaceuticals SA

Mithra enters into exclusive negotiations with Gedeon Richter and secures continued funding in the context of its monetization process

03 May 2024 11:30:00 By Nasdaq GlobeNewswire

Mithra reports full year 2023 financial results

08 Mar 2024 01:00:00 By Nasdaq GlobeNewswire

Mithra announces changes to its executive management

05 Mar 2024 01:01:00 By Nasdaq GlobeNewswire

Mithra initiates monetization process, receives bridge loan from existing lenders

05 Mar 2024 01:00:00 By Nasdaq GlobeNewswire

DONESTA® safety study for menopause completes treatment phase and advances to data management & reporting phase

29 Feb 2024 05:42:16 By Nasdaq GlobeNewswire

Mithra sells shares in Mayne Pharma

15 Feb 2024 12:23:05 By Nasdaq GlobeNewswire

Mithra updates on cash position

06 Feb 2024 01:00:00 By Nasdaq GlobeNewswire

Mithra and Rafa Laboratories sign binding Head of Terms to commercialize DONESTA® in Israel

21 Dec 2023 11:45:00 By Nasdaq GlobeNewswire

Mithra Completes Pediatric Study of ESTELLE® in Adolescent Patients

20 Dec 2023 11:45:00 By Nasdaq GlobeNewswire

Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial

18 Dec 2023 01:00:00 By Nasdaq GlobeNewswire

Mithra and Gedeon Richter sign binding Head of Terms to commercialize ESTELLE® and DONESTA® in China

04 Dec 2023 01:00:00 By Nasdaq GlobeNewswire

Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States

30 Nov 2023 01:00:00 By Nasdaq GlobeNewswire

Mithra to hold five presentations on key role of estrogens in women’s health, including Estetrol (E4), at the ESG Congress in Amsterdam

28 Nov 2023 11:45:00 By Nasdaq GlobeNewswire

Mithra’s NEXTSTELLIS® granted additional patent in the United States

07 Nov 2023 01:00:00 By Nasdaq GlobeNewswire

Mithra releases invitation to its extraordinary securities holders’ meeting

06 Nov 2023 12:52:53 By Nasdaq GlobeNewswire

Mithra and Searchlight Pharma sign DONESTA® licensing agreement for Canada

26 Oct 2023 01:00:00 By Nasdaq GlobeNewswire

Mithra to receive EUR 2.5 million milestone payment from Fuji Pharma under ESTELLE® licensing agreement

23 Oct 2023 01:00:00 By Nasdaq GlobeNewswire

Mithra’s Board of Directors to propose the removal of its request for change of the remuneration policy at the Special General Meeting

17 Oct 2023 01:00:00 By Nasdaq GlobeNewswire

Shareholder Letter

11 Oct 2023 01:15:00 By Nasdaq GlobeNewswire

Mithra announces update to the agenda of its upcoming special general shareholders’ meeting

11 Oct 2023 01:00:00 By Nasdaq GlobeNewswire